# Safety and Efficacy of Transulnar Route in Percutaneous Coronary Intervention: 30 days follow-up

Raghava Sarma Polavarapu<sup>1</sup>, MD, DM; Yudhistar Siripuram<sup>2</sup>, MD, DM; Keerthika Chowdary Ravella<sup>3</sup>, MD, DM; Anurag Polavarapu<sup>4</sup>, MD, DM; Kalyan Chakravarthi Pulivarthi<sup>5</sup>, MD, DM; Hima Sanjana Perumalla<sup>6</sup>, MBBS; Sai Reshma Magam<sup>7</sup>, MD; Vijaya Pamidimukkala <sup>8</sup>, MD, DM

<sup>1</sup>Interventional Cardiologist, Head of Department, Department of Cardiology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh -522001, India

<sup>2</sup>Junior Consultant., Department of Cardiology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh -522001, India

<sup>3</sup>Senior Consultant, Department of Cardiology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh -522001, India

<sup>4</sup>Senior Resident, Department of Cardiology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh -522001, India

<sup>5</sup>Junior Consultant Cardiology, Department of Cardiology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh -522001, India

<sup>6</sup>Physician, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh -522001, India
<sup>7</sup>Resident, Internal Medicine, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh -522001, India
<sup>8</sup>Head of Department, Department of Neurosciences, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh -522001, India

Corresponding Author: Raghava Sarma Polavarapu

DOI: https://doi.org/10.52403/ijrr.20221130

#### **ABSTRACT**

**Background** Percutaneous coronary intervention (PCI) is the mainstay treatment in patients with coronary artery disease (CAD). The utility of transulnar approach (TUA) has been a topic of debate. Therefore, we aimed to evaluate the safety and efficacy of TUA in this study.

**Methods** This was a prospective, single-center, conducted interventional study between September 2005 and November 2021 at a tertiary-care center in India. Consecutive patients (≥18 years) with CAD requiring PCI using TUA were enrolled in this study. Patients with a negative Allen's or reverse Allen's test (>10 seconds), nonpalpable ulnar artery, cardiogenic shock, and the need for a large guiding catheter were excluded. Patients were clinically followed-up at one week to monitor occlusion and 30 days to observe and manage major adverse cardiovascular events (MACE; composite of myocardial re-infarction, target

vessel revascularization, disabling stroke, and death).

Results A total of 200 patients were enrolled in this study with a mean age of 58.2±10.7 years. Majority of patients (38%) belonged to the age group of 56-65 years and this study observed a male predominance (80.5%). Follow-up of one week revealed no anatomical variations of the ulnar artery and there was no trauma to the ulnar nerve. Ulnar occlusion, however, was seen in three (1.5%) patients. Forearm hematoma was observed in one patient which was then managed conservatively. At 30-days follow-up, (MACE) did not occur in any of the patients.

**Conclusion** In the case that TRA cannot be performed, TUA can be used as a safe and effective alternative access route for PCI, avoiding the transfemoral approach.

*Keywords:* Coronary artery disease, catheterization, transulnar approach, transradial approach

#### INTRODUCTION

Coronary artery disease (CAD) is the leading cause of mortality and morbidity worldwide.(1) One of the commonly used techniques to enhance myocardial perfusion percutaneous CAD is coronary intervention (PCI).(2) Well-established arteries for performing PCI are the femoral (transfemoral) and radial (transradial) arteries. Just about two decades ago, Terashima and colleagues performed PCI using the ulnar artery (transulnar) for the first time.(3) The need for this new approach stemmed from the drawbacks of earlier approaches. Bleeding complications are higher with femoral access and there may be other hindrances to this route such as the presence of active groin infection, prior surgery, radiation therapy to the groin, and presence of iliac or aortoiliac aneurysms, etc.(4) In such events, the transradial approach (TRA) is preferred. However, vascular occlusion is seen in approximately 6% of patients undergoing TRA, necessitating repeat PCI via the procedures through a different artery or another femoral radial artery.(5) Moreover, TRA may not be feasible for patients with an abnormal Allen's test, anatomical variations in the radial artery, synovial cysts, local hematomas, and aberrant origin.(6) There has been debate regarding whether TRA and transulnar approach (TUA) are equally safe and effective routes, and whether TUA can be employed when TRA is not feasible. Previous studies have found that TUA and TRA are equally safe and efficacious and that TUA should be considered when the risk of failure via TRA is high.(7, 8) In this study, we aimed to check the rates of switching to another route and the long-term outcomes of performing PCI via TUA in consecutive patients with a broad inclusion.

## **METHODS**

## Study Design and Participants

This prospective, single-center, interventional study was conducted between September 2005 and November 2021 at a

tertiary-care center in India. During this time, 200 consecutive CAD patients (≥18 years) requiring PCI using the translunar route were enrolled in this study. The study was approved by Institutional Ethics Committee and was conducted in accordance with the Declaration of Helsinki. At the time of the index procedure, written informed consent was obtained from all patients or their designees.

Patients with a negative Allen's or reverse Allen's test (>10 seconds), nonpalpable ulnar artery, cardiogenic shock, and patients with the need for a large guiding catheter were excluded.

# Procedure and follow-up

The Allen and reverse Allen tests at the initially attempted forearm were performed in all patients with a cut-off time of  $\leq 10$ seconds for normal post-ischemic palmar perfusion to estimate the adequacy of the ulnar-dependent and transradial-dependent circulation, collateral respectively. Indication for TUR was given when Allen's test was positive for radial artery. 6F sheaths (Terumo Corporation, Japan) and guiding catheters were used. Intravenous loading dose of aspirin (300 mg) and clopidogrel (150-300 mg) were given preprocedure. Post-PCI, aspirin (150 mg/day) clopidogrel mg/day) (75 prescribed for at least 12 months followed by aspirin indefinitely.

Procedural success was defined thrombolysis in myocardial infarction (TIMI) grade 3 flow. Ulnar artery was examined clinically on the day of the procedure and at one-week follow-up. Detailed examination for ulnar nerve was also done at scheduled one-week follow-up and ulnar nerve injury, if any, was noted. Procedural complications such as vascular occlusion, hematoma at the access site and forearm. arteriovenous fistula. pseudoaneurysm, were also recorded. Clinically impalpable pulse at one week was labeled as artery occlusion. Patients were also followed-up at 30 days for clinical events.

## Endpoints and definitions

The primary outcome was major adverse cardiac events (MACE), a composite of myocardial re-infarction, target revascularization, disabling stroke, death. Myocardial reinfarction was defined by recurrent clinical signs and symptoms of ischemia distinct from the index event. concomitant along with electrocardiographic changes and serum evidence biomarker of myocardial necrosis.(9) Disabling stroke was defined as stroke requiring inpatient rehabilitation or skilled nursing care.(10) Target vessel revascularization was defined as unplanned repeat PCI or bypass graft implantation for stenosis in a different area of the vessel treated at the index PCI.(11)

#### STATISTICAL ANALYSIS

All variables were analyzed and expressed as numbers (n) and percentages (%). Continuous variables displaying normal distribution were expressed as mean  $\pm$  SD. Statistical analyses were performed using Statistical Package for Social Sciences version 21.0 (IBM, Chicago, IL, USA).

## **RESULTS**

The mean age of patients was  $58.2\pm10.7$  years and majority of patients (38%) belonged to the age group of 56-65 years. This study observed a male predominance (80.5%). Out of all patients, 74 (37%) had hypertension and 84 (42%) had diabetes mellitus. The complete baseline and clinical characteristics of all the patients are outlined in **Table 1**.

**Table 1: Patient characteristics** 

Characteristic (N=200)	n (%)
Age, n (%)	
≤45 years	27 (13.5)
46-55 years	49 (24.5)
56-65 years	76 (38)
66-75 years	31 (15.5)
>75 years	17 (8.5)
Gender, n (%)	
Male	161 (80.5)
Female	39 (19.5)
Hypertension, n (%)	74 (37)
Diabetes mellitus, n (%)	84 (42)
Smoking, n (%)	97 (48.5)
Clinical presentation, n (%)	
Unstable angina	93 (46.5)
NSTEMI	89 (44.5)
STEMI	18 (9)
Culprit vessel , n (%)	
Left anterior descending artery	102 (51)
Right coronary artery	67 (33.5)
Left circumflex artery	29 (14.5)
Left main	2(1)
Multivessel disease, n (%)	32 (16)
Pre-PCI TIMI flow grade, n (%)	
≤1	169 (84.5)
≥2	31 (15.5)
Post-PCI TIMI flow grade, n (%)	
3	200 (100)
≤2	0 (0)

NSTEMI: Non-ST elevated myocardial infarction; STEMI: ST-elevated myocardial infarction; PCI: Percutaneous coronary intervention; TIMI: Thrombolysis in myocardial infarction

Majority of patients were diagnosed with unstable angina (46.5%), followed by non-ST elevation myocardial infarction (44.5%). The most common culprit vessel was left anterior descending artery, affecting 102

patients (51%), and 32 patients (16%) had multivessel disease. Prior to PCI, 169 patients (84.5%) had a TIMI flow  $\leq$ 1, and post-procedure, all patients had TIMI 3 flow. In 196 patients, the intervention was

performed via the right ulnar artery, while 4 patients were accessed via the left ulnar artery.

Follow-up of one week revealed no anatomical variations of the ulnar artery and there was no trauma to the ulnar nerve. Ulnar occlusion, however, was seen in three (1.5%) patients. Other vascular complications following PCI are given in **Table 2**. Forearm hematoma was observed in one patient which was then managed conservatively. At 30-days follow-up, no MACE was reported in any of the patients.

Table 2: Vascular complications following percutaneous coronary intervention

CHUOH	
Complication, n (%)	n (%)
Pseudoaneurysm	0 (0)
Access site hematoma	0 (0)
Forearm hematoma	1 (0.5)
Severe artery spasm	0 (0)
Ulnar occlusion	3 (1.5)

#### **DISCUSSION**

TRA is a frequently employed and wellestablished strategy for elective PCI. Over the last two decades, TUA has gained attention as an alternative route to TRA. This route has several advantages and disadvantages which need to be taken into consideration.

The mean age of patients in our study was 58.2±10.7 years which was comparable with the age of patients in a study conducted by Liu et al.  $(58.6\pm11.5 \text{ years})$ .(6) In this study, we had a high success rate of ulnar cannulation. Notably, we did not observe a single case of ulnar artery spasms as opposed to the spasms noted by Shafiq et al.(12) and Varenne et al.(13) in TRA. This may be attributed to the fact that there are fewer alpha-adrenergic receptors in the transulnar route as compared to transradial route. Secondly, the ulnar artery has a diameter greater than that of the radial artery, and hence, it can accommodate catheter sizes up to 7F, although we restricted the size to 6F only. Liu et al. (6) have also noted the lower prevalence of vasospasm in the transulnar route. The higher prevalence of spasms in the TRA may be due to its smaller size and greater tortuosity.(14)

The second most prominent finding of our study was that there was no need for crossover to femoral route. On the contrary, a study conducted by Hahalis et al. in the AURA of ARTEMIS study (15) concluded that the TUR was inferior to TRA because of greater crossover rates in the former (9.4% vs. 4.1%, OR 1.92, 95% CI [0.91, 4.06], P = 0.09,  $I^2 = 87\%$ ). A meta-analysis by Sedhom et al.(7) also found that TUA had higher crossover rates than the TRA (P = 0.09). However, Bhanwar et al.(5) allied with our finding that the ulnar approach reduces crossover rates.

In the current study, we observed one forearm hematoma (0.5%) (not life and limb threatening) which required conservative management. The observed percentage was much lower than what Roghani-Dehkordi et al. (14) and Shafiq et al.(12) found (10.4% and 2.5%, respectively). Presence of large hematomas may compress the ulnar nerve, owing to its proximity to the ulnar artery, leading to paresthesia and possible motor dysfunction. Although the hematoma was not serious in our study, Sedhom et al. (7) found a significantly higher occurrence of major hematomas in patients accessed via the TUR compared to the TRA (P = 0.24). At 30-days follow-up, we found no occurrence of MACE (myocardial reinfarction, target vessel revascularization, disabling stroke, and death). At 60 days, Hahalis et al. found that the transulnar route non-inferior to transradial route according to per-protocol and intention-totreat analyses.(15)

This study should be considered in the light of its limitations. First, this was a single-center study with a limited number of patients. Secondly, there was no control arm to compare TUA with TRA. Therefore, further studies should include larger number of patients and a control group of TRA to validate our findings.

#### **CONCLUSION**

Taken together, our results add to the existing knowledge that TUA has good success rates, lower MACE occurrence, and lesser chances of hematological complications. TUA can be used as a safe and effective alternative in patients undergoing PCI in the event that TRA cannot be used, avoiding the need for a transfemoral approach.

**Acknowledgement:** None

**Conflict of Interest:** None

**Source of Funding: None** 

Ethical Approval: Approved

### **REFERENCES**

- 1. World Health Organization. Cardiovascular diseases (CVDs) 2021, June 11 [Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)#:~:text=Cardiovascular% 20 diseases % 20 (CVDs)% 20 are% 20 the,-% 20 and% 20 middle-income% 20 countries.
- 2. Khan SQ, Ludman PF. Percutaneous coronary intervention. Medicine. 2022.
- 3. Terashima M, Meguro T, Takeda H, Endoh N, Ito Y, Mitsuoka M, et al. Percutaneous ulnar artery approach for coronary angiography: a preliminary report in nine patients. Catheter Cardiovasc Interv. 2001; 53(3):410-4.
- 4. Bangalore S, Bhatt DL. Femoral arterial access and closure. Circulation. 2011; 124(5):e147-e56.
- 5. Ranwa BL, Priti K. Transulnar versus transradial access as a default strategy for percutaneous coronary intervention. Heart Views. 2019;20(4):152.
- 6. Liu J, FU XH, Xue L, WU WL, GU XS, LI SQ. A comparative study of transulnar and transradial artery access for percutaneous coronary intervention in patients with acute coronary syndrome. J Interv Cardiol. 2014;27(5):525-30.
- 7. Sedhom R, Megaly M, Abraham B, George JC, Kalra S, Janzer S. Transulnar versus transradial access for coronary angiography and percutaneous coronary intervention: a meta-analysis of randomized controlled

- trials. Cardiovasc Revasc Med. 2021;26:39-45.
- 8. Fernandez R, Zaky F, Ekmejian A, Curtis E, Lee A. Safety and efficacy of ulnar artery approach for percutaneous cardiac catheterization: systematic review and meta-analysis. Catheterization and Cardiovascular Interventions. 2018;91(7): 1273-80.
- 9. Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross Jr JT, Drozda Jr JP, et al. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Circulation. 2013;127(9):1052-
- Kim AS, Klingman JG, Sidney S, Johnston SC. Abstract TMP57: Disabling Stroke is Uncommon After An Emergency Department Evaluation and Discharge for Dizziness Symptoms. Am Heart Assoc; 2013.
- 11. Alhejily WA, Ohman EM. Repeat Revascularization After PCI: Are We Reinventing the Wheel or Redefining Achilles' Heel? : Am Heart Assoc; 2012. p. 746-7.
- 12. Shafiq M, Mahmoud HB, Fanous ML. Percutaneous trans-ulnar versus trans-radial arterial approach for coronary angiography and angioplasty, a preliminary experience at an Egyptian cardiology center. Egypt Heart J. 2020;72(1):1-7.
- 13. Varenne O, Jégou A, Cohen R, Empana JP, Salengro E, Ohanessian A, et al. Prevention of arterial spasm during percutaneous coronary interventions through radial artery: the SPASM study. Catheter Cardiovasc Interv. 2006;68(2):231-5.
- 14. Roghani-Dehkordi F, Mansouri R, Khosravi A, Mahaki B, Akbarzadeh M, Kermani-Alghoraishi M. Transulnar versus transradial approach for coronary angiography and angioplasty: Considering their complications. ARYA Atheroscler. 2018;14(3):128.
- 15. Hahalis G, Tsigkas G, Xanthopoulou I, Deftereos S, Ziakas A, Raisakis K, et al.

Transulnar Compared With Transradial Artery Approach as a Default Strategy for Coronary Procedures: A Randomized Trial The Transulnar or Transradial Instead of Coronary Transfemoral Angiographies Study (The AURA of ARTEMIS Study). Circ Cardiovasc Interv. 2013;6(3):252-61.

How to cite this article: Raghava Sarma Polavarapu, Yudhistar Siripuram, Keerthika Chowdary Ravella et.al. Safety and efficacy of Transulnar route in percutaneous coronary intervention: 30 days follow-up. *International Journal of Research and Review*. 2022; 9(11): 226-231.

DOI: https://doi.org/10.52403/ijrr.20221130

\*\*\*\*\*